Inseparable in Disease, Yet Treated Apart: A Retrospective Study of a Cardiorenal Cohort at a Tertiary University Hospital
Journal of CardioRenal Medicine · 2025
DOI: 10.3390/jcrm1010005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of CardioRenal Medicine, 2025. Verfasst von Christian Martinetti und 5 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The prevalence of cardiorenal syndrome (CRS) and its management might be challenging, so an interdisciplinary approach is advocated. The aim of this study was to identify and describe the population which might profit from such an interdisciplinary clinic at the University Hospital of Zürich.
Methods
We screened 551 patients who were seen at least once in the nephrology and cardiology outpatient clinics from 2015 to 2022. Patients with kidney (87) or heart (47) transplantation, on dialysis (179), without concomitant chronic kidney disease (CKD) and heart failure (HF) (179), and those who died before the end of follow-up (94), were excluded, resulting in a cohort of 150 patients. Characteristics related to the type and cause of renal and cardiac disease, cardiovascular risk factors, adequacy of therapy, and incidence of hospitalization for HF were recorded.
Results
The median age of the population was 71 years, with one-third having diabetes and two-thirds being male. The median BMI was 28 kg/m2. The predominant cause of chronic kidney disease (CKD) was cardiorenal syndrome type 2, affecting 44% (66 out of 150 patients). At the start of the follow-up, the distribution of CKD stages was as follows: 52 patients (34.7%) had CKD stage 2, 30 (20%) had CKD stage 3a, 21 (14%) had CKD stage 3b, 11 (7.3%) had CKD stage 4, and 1 (0.6%) had CKD stage 5. Notably, 81 patients (54%) had moderate or severe albuminuria. Ischemic cardiomyopathy was the leading cause of heart failure, affecting 36.4% (47 patients). Among the heart failure classifications, 73 patients (48.7%) had HFrEF, 32 (21.3%) had HFmrEF, and 45 (30%) had HFpEF. A total of 54 patients (36%) were treated with SGLT2 inhibitors, while 116 (77.3%) received RAAS inhibitors, including 32 patients (21.3%) on an ARNI. Those using both RAAS inhibitors and SGLT2 inhibitors were younger (average age 66 vs. 73 years, p = 0.005) and had a higher prevalence of diabetes (44% vs. 30%) and HFrEF compared to HFpEF (70% vs. 7%, p = 0.002). The hospitalization rate was notably high at 2.2 admissions per patient per year, with an incidence of acute kidney injury (AKI) at 0.23 events per patient per year.
Conclusions
We identified a high-risk patient population with cardiorenal disease that might particularly benefit from evidence-based and patient-centered interdisciplinary care.
Zitieren
APA
Martinetti, C., George, B., Schachtner, T., Ruschitzka, F., Frank, M., & Rho, E. (2025). Inseparable in Disease, Yet Treated Apart: A Retrospective Study of a Cardiorenal Cohort at a Tertiary University Hospital. Journal of CardioRenal Medicine. https://doi.org/10.3390/jcrm1010005
Vancouver
Martinetti C, George B, Schachtner T, Ruschitzka F, Frank M, Rho E. Inseparable in Disease, Yet Treated Apart: A Retrospective Study of a Cardiorenal Cohort at a Tertiary University Hospital. Journal of CardioRenal Medicine. 2025. doi:10.3390/jcrm1010005
BibTeX
@article{Martinetti2025,
author = {Martinetti, Christian and George, Britta and Schachtner, Thomas and Ruschitzka, Frank and Frank, Michelle and Rho, Elena},
title = {Inseparable in Disease, Yet Treated Apart: A Retrospective Study of a Cardiorenal Cohort at a Tertiary University Hospital},
journal = {Journal of CardioRenal Medicine},
year = {2025},
doi = {10.3390/jcrm1010005}
}
EUVIMED